The therapeutic community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s demonstrating significant promise in clinical trials for addressing obesity. Unlike some current weight loss approaches, retatrutide appears to deliver a greater substantial lo